MARKET

TVRD

TVRD

Tvardi Therapeutics Inc
NASDAQ
2.710
+0.010
+0.37%
After Hours: 2.710 0 0.00% 19:06 06/11 EDT
OPEN
2.700
PREV CLOSE
2.700
HIGH
2.760
LOW
2.610
VOLUME
35.97K
TURNOVER
--
52 WEEK HIGH
43.65
52 WEEK LOW
2.610
MARKET CAP
25.42M
P/E (TTM)
-1.6984
1D
5D
1M
3M
1Y
5Y
1D
This Cerebras Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday
Benzinga · 3d ago
Tvardi Therapeutics Price Target Announced at $9.00/Share by HC Wainwright & Co.
Dow Jones · 4d ago
Tvardi Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow Jones · 4d ago
HC Wainwright & Co. Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $9
Benzinga · 4d ago
Weekly Report: what happened at TVRD last week (0601-0605)?
Weekly Report · 4d ago
TVARDI THERAPEUTICS, INC. <TVRD.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING AND TARGET PRICE $9
Reuters · 4d ago
Tvardi Therapeutics initiated with a Buy at H.C. Wainwright
TipRanks · 4d ago
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex
Reuters · 4d ago
More
About TVRD
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Webull offers Tvardi Therapeutics Inc stock information, including NASDAQ: TVRD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVRD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVRD stock methods without spending real money on the virtual paper trading platform.